Previous Close | 1.5000 |
Open | 2.0000 |
Bid | 1.4500 |
Ask | 4.6000 |
Strike | 45.00 |
Expire Date | 2024-05-17 |
Day's Range | 1.8000 - 2.2500 |
Contract Range | N/A |
Volume | |
Open Interest | 326 |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Insights into SWTX's robust Q1 performance, strategic initiatives, and forward-looking financial health.
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc